| Name | CY 208-243,(-)-(6aR,12bR)-4,6,6a,7,8,12b-Hexahydro-7-methylindolo[4,3-a]phenanthridin |
|---|---|
| Synonyms | SynaptoRedTM C2 |
| Description | CY 208-243 is a selective dopamine D1 receptor agonist which exhibits antiparkinsonian activity[1]. |
|---|---|
| Related Catalog | |
| Target |
dopamine D1 receptor[1] |
| In Vivo | Pretreatment with CY 208-243 (2.5 mg/kg; s.c.) prevents the increase of DA release and metabolism induced by the D-1 antagonist, SCH 23390 (0.05 mg/kg; s.c.)[1]. Animal Model: Male Sprague-Dawley rats (180-200 g)[1] Dosage: 2.5 mg/kg Administration: Subcutaneous Result: Prevented the increase of DA release and metabolism induced by the D-1 antagonist. |
| References |
| Density | 1.225 g/cm3 |
|---|---|
| Boiling Point | 466.5ºC at 760 mmHg |
| Melting Point | 227-228ºC |
| Molecular Formula | C19H18N2 |
| Molecular Weight | 274.36000 |
| Flash Point | 236ºC |
| Exact Mass | 274.14700 |
| PSA | 19.03000 |
| LogP | 3.60780 |
| Vapour Pressure | 7.02E-09mmHg at 25°C |
| Index of Refraction | 1.697 |
| Precursor 1 | |
|---|---|
| DownStream 0 | |